Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ACRS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not… NCT07935590 · Lichen Planus Modzatinib, Placebo | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Not yet recruiting | 102 | Mar 2029 | Registry ↗ |
| Sep 29, 2026 | ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis NCT07011706 · Atopic Dermatitis, Atopic ATI-045, Placebo | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Active, not recruiting | 110 | Sep 21, 2026 | Registry ↗ |
| Sep 28, 2026 | ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Act… NCT05279417 · Rheumatoid Arthritis ATI-450 50 mg oral tablet BID, Placebo oral tablet | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 251 | Sep 5, 2023 | Registry ↗ |
| Mar 12, 2026 | Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis NCT06585202 · Atopic Dermatitis ATI-2138 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 14 | Mar 13, 2025 | Registry ↗ |
| Jan 7, 2026 | ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) NCT05216224 · Hidradenitis Suppurativa ATI-450, Placebo oral tablet | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 95 | Dec 23, 2022 | Registry ↗ |
| Nov 27, 2024 | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis NCT05511519 · Psoriatic Arthritis ATI-450, Placebo Oral Tablet | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Terminated | 47 | Dec 6, 2023 | Registry ↗ |
| Oct 26, 2024 | Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis NCT05432596 · Atopic Dermatitis ATI-1777 2.0% w/w, ATI-1777 1.0% w/w | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 250 | Oct 26, 2023 | Registry ↗ |
| Sep 28, 2023 | Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis NCT04598269 · Atopic Dermatitis ATI-1777, Vehicle | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 50 | Apr 8, 2021 | Registry ↗ |
| Sep 21, 2023 | Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) NCT04524858 · Cryopyrin-Associated Periodic Syndrome ATI-450 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Terminated | 1 | Feb 25, 2021 | Registry ↗ |
| Mar 29, 2023 | Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA NCT04247815 · Rheumatoid Arthritis ATI-450, Placebo oral tablet | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 25 | Feb 4, 2021 | Registry ↗ |
| Dec 9, 2020 | A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solut… NCT03495817 · Androgenetic Alopecia ATI-50002 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 31 | Oct 15, 2019 | Registry ↗ |
| Dec 2, 2020 | Study of A-101 for the Treatment of Seborrheic Keratosis NCT02260180 · Seborrheic Keratosis A-101 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 119 | Mar 2015 | Registry ↗ |
| Nov 30, 2020 | A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo NCT03468855 · Vitiligo ATI-50002 topical solution | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 34 | Oct 16, 2019 | Registry ↗ |
| Nov 23, 2020 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts NCT03812510 · Common Wart A-101 | ACRS Aclaris Therapeutics, Inc. | Phase 3 | Completed | 426 | Nov 27, 2019 | Registry ↗ |
| Oct 27, 2020 | A Study of A-101 Topical Solution for the Treatment of Common Warts NCT03691831 · Common Wart Active, Vehicle | ACRS Aclaris Therapeutics, Inc. | Phase 3 | Completed | 502 | Apr 21, 2019 | Registry ↗ |
| Oct 6, 2020 | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and A… NCT03759340 · Alopecia Areata, Alopecia Universalis ATI 502 0.46% Topical Solution | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Terminated | 56 | Sep 11, 2019 | Registry ↗ |
| Oct 5, 2020 | Study of A-101 Topical Solution for the Treatment of Common Warts NCT03687372 · Common Wart A-101, vehicle | ACRS Aclaris Therapeutics, Inc. | Phase 3 | Completed | 503 | Jun 20, 2019 | Registry ↗ |
| Sep 16, 2020 | ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis… NCT03594227 · Alopecia ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose) | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 87 | Jun 6, 2019 | Registry ↗ |
| Jul 2, 2020 | Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopec… NCT03315689 · Alopecia Universalis (AU), Alopecia Totalis (AT) Vehicle, ATI-50002 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 11 | Jun 20, 2019 | Registry ↗ |
| Jun 5, 2020 | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata NCT03354637 · Alopecia Areata ATI-50002 high dose, ATI-50002 low dose | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Terminated | 129 | Apr 18, 2019 | Registry ↗ |
| Mar 30, 2020 | A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra NCT03224598 · Dermatosis Papulosa Nigra A-101 Topical Solution 40% | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 39 | Jan 8, 2019 | Registry ↗ |
| Feb 17, 2020 | A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis NCT03585296 · Atopic Dermatitis ATI-502 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 22 | Apr 25, 2019 | Registry ↗ |
| Dec 11, 2019 | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due… NCT03551821 · Alopecia Areata, Alopecia Totalis ATI-50002 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 1 | Nov 6, 2018 | Registry ↗ |
| Oct 2, 2019 | An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses NCT03487588 · Seborrheic Keratosis A-101 Topical Solution | ACRS Aclaris Therapeutics, Inc. | Phase 4 | Completed | 41 | Nov 14, 2018 | Registry ↗ |
| Sep 4, 2019 | Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea NCT03380390 · Rosacea Oxymetazoline HCL 1.0% Cream, Energy-Based Therapy | ACRS Aclaris Therapeutics, Inc. | Phase 4 | Completed | 46 | Jun 15, 2018 | Registry ↗ |
| May 6, 2019 | A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic… NCT03148691 · Seborrheic Keratosis A-101 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 253 | Feb 28, 2018 | Registry ↗ |
| May 1, 2019 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts NCT03210337 · Common Wart A-101 Topical Solution, A-101 Vehicle Solution | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 157 | Mar 16, 2018 | Registry ↗ |
| Apr 9, 2019 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts NCT03278028 · Common Wart A-101 Topical Solution, A-101 Vehicle Solution | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 159 | Mar 1, 2018 | Registry ↗ |
| Jan 3, 2019 | Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis NCT02160626 · Seborrheic Keratosis A-101 Vehicle, A-101 (40) Topical Solution | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 172 | Dec 2014 | Registry ↗ |
| Dec 11, 2018 | Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis NCT01986920 · Seborrheic Keratosis (SK) A-101 25%, A-101 32.5% | ACRS Aclaris Therapeutics, Inc. | Phase 1/2 | Completed | 35 | Feb 25, 2014 | Registry ↗ |
| Dec 7, 2018 | A Study of A-101 Solution in Subjects With Common Warts. NCT02669862 · Common Warts A-101 Solution 40, A-101 Solution 45 | ACRS Aclaris Therapeutics, Inc. | Phase 2 | Completed | 98 | Sep 16, 2016 | Registry ↗ |
| Feb 7, 2018 | An Open-Label Safety Study of A-101 Solution NCT02667288 · Seborrheic Keratosis A-101 Solution | ACRS Aclaris Therapeutics, Inc. | Phase 3 | Completed | 147 | Oct 2016 | Registry ↗ |
| Feb 6, 2018 | A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis NCT02667275 · Seborrheic Keratosis A-101 Solution, Vehicle Solution | ACRS Aclaris Therapeutics, Inc. | Phase 3 | Completed | 487 | Oct 2016 | Registry ↗ |
| Feb 6, 2018 | A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. NCT02667236 · Seborrheic Keratosis A-101 Solution, Vehicle Solution | ACRS Aclaris Therapeutics, Inc. | Phase 3 | Completed | 450 | Oct 2016 | Registry ↗ |
34 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances